Contact
Please use this form to send email to PR contact of this press release:
Opiant Pharmaceuticals Announces Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose
TO:
Please use this form to send email to PR contact of this press release:
Opiant Pharmaceuticals Announces Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose
TO: